‘Life-changing’ cystic fibrosis drugs to be made available on NHS

The Cystic Fibrosis Trust said the news followed many years of campaigning by people affected by the condition.

“Life-changing” drugs to treat cystic fibrosis will routinely be available on the NHS after an agreement was made on their price.

The National Institute for Health and Care Excellence (Nice) said last November that the treatments were clinically effective but were too expensive at the list price for it to recommend them.

But in a development on Thursday, the pharmaceutical firm Vertex announced it had reached a long-term reimbursement agreement with NHS England over Orkambi, Symkevi and Kaftrio, enabling them to be approved on the NHS.

Nice was also able to use a new method to evaluate the drugs which means it can give extra weight to health benefits from medicines for treating the most severe diseases such as cystic fibrosis.

Vertex, NHS England and Nice have also committed to work together on rapid access for all eligible patients for the new triple therapy vanzacaftor/tezacaftor/deutivacaftor, which is currently being evaluated by medicines regulators.

Vertex said it was working with the NHS in Scotland, Wales and Northern Ireland to finalise similar access agreements as soon as possible.

The Cystic Fibrosis Trust said the move would give people access to the “life-changing” drugs and followed many years of campaigning by people affected by the condition.

David Ramsden, chief executive of the charity, said: “This is a fantastic moment for many people with cystic fibrosis and their families – ending uncertainty and helping to ensure that everyone who can benefit is able to access these vital medicines, now and in the future.

“We should not forget though that these treatments are not a cure and simply don’t work for some people.

“With the support of our incredible community, clinicians and researchers a lot has been achieved but we know there is still lots more to do.”

Cystic fibrosis is an inherited condition that causes sticky mucus to build up in the lungs and digestive system.

It can cause serious lung infections and people can often have problems digesting food.

Symptoms usually start in early childhood and the condition gets worse over time.

There is no cure for the condition.

Nice has published a full list of who is eligible for the drugs, which can be given in childhood.

Around 8,200 people are already on the treatments in England and will continue to be able to get them on the NHS.

The drugs will also be available to people who are diagnosed with cystic fibrosis in the future.

More than 11,000 people in the UK have the condition.

More from Perspective

Get a free copy of our print edition


Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.
You need to agree with the terms to proceed

Your email address will not be published. The views expressed in the comments below are not those of Perspective. We encourage healthy debate, but racist, misogynistic, homophobic and other types of hateful comments will not be published.